NFA
LCTX icon

Nationwide Fund Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Nationwide Fund Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-95,513
Closed -$237K – 1136
2017
Q3 		$237K Buy
95,513
+13,380
+16% +$33.2K ﹤0.01% 2560
2017
Q2 		$226K Buy
82,133
+31,180
+61% +$87.1K ﹤0.01% 2575
2017
Q1 		$154K Buy
50,953
+1,074
+2% +$3.05K ﹤0.01% 2691
2016
Q4 		$158K Sell
49,879
-5,248
-10% -$16.1K ﹤0.01% 2711
2016
Q3 		$188K Buy
55,127
+12,273
+29% +$33.9K ﹤0.01% 2655
2016
Q2 		$98K Buy
42,854
+4,105
+11% +$10.1K ﹤0.01% 2919
2016
Q1 		$97K Sell
38,749
-3,013
-7% -$6.72K ﹤0.01% 2833
2015
Q4 		$138K Hold
41,762
– – ﹤0.01% 2722
2015
Q3 		$101K Hold
41,762
– – ﹤0.01% 2893
2015
Q2 		$122K Sell
41,762
-5,638
-12% -$21.9K ﹤0.01% 2953
2015
Q1 		$190K Sell
47,400
-1,934
-4% -$6.69K ﹤0.01% 2713
2014
Q4 		$149K Hold
49,334
– – ﹤0.01% 2777
2014
Q3 		$125K Buy
49,334
+969
+2% +$2.33K ﹤0.01% 2900
2014
Q2 		$119K Buy
48,365
+12,384
+34% +$28K ﹤0.01% 2975
2014
Q1 		$96K Hold
35,981
– – ﹤0.01% 2747
2013
Q4 		$105K Hold
35,981
– – ﹤0.01% 2939
2013
Q3 		$110K Buy
35,981
+3,183
+10% +$10.1K ﹤0.01% 2905
2013
Q2 		$105K Buy
+32,798
New +$105K ﹤0.01% 2782

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nationwide Fund Advisors's LCTX Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2017, closing a stake of 95,513 shares — an estimated $237K sold.

Nationwide Fund Advisors first reported a position in LCTX in Q2 2013 and held it in 18 quarters. The position peaked at $237K in Q3 2017. 117 funds tracked by Wall St. Rank hold LCTX as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 95,513 Lineage Cell Therapeutics shares in Q4 2017, an estimated $237K.
  • Nationwide Fund Advisors first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 18 quarters.
  • Nationwide Fund Advisors's Lineage Cell Therapeutics position peaked at $237K in Q3 2017.
  • 117 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.